国际眼科纵览 ›› 2024, Vol. 48 ›› Issue (4): 248-254.doi: 10.3760/cma.j.issn.1673-5803.2024.04.002

• 综述 • 上一篇    下一篇

微小RNA在青光眼研究中的应用

吴仁毅1,2,3  高茹心1   

  1. 1厦门大学附属厦门眼科中心 福建省眼表与角膜病重点实验室 厦门市眼表与角膜疾病重点实验室 厦门市眼部疾病临床医学研究中心 厦门市眼部疾病重点实验室,厦门 361001; 2宁波鄞州眼科医院,宁波 315199; 3上海和平眼科医院,上海 200437

  • 收稿日期:2024-02-22 出版日期:2024-08-22 发布日期:2024-08-08
  • 通讯作者: 吴仁毅,Email:wubasel@hotmail.com
  • 基金资助:
    厦门市自然科学基金(3502Z202374133);华厦科研基金(HXKY202301D004,HXKY202306A003)

Application prospects of microRNAs in glaucoma research

Wu Renyi1,2,3, Gao Ruxin1   

  1. 1Institute and Affiliated Xiamen Eye Center of Xiamen University, Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Municipal Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen Research Center for Eye Diseases and Key Laboratory of Ophthalmology, Xiamen 361001, China; 2 Ningbo Yinzhou Eye Hospital, Ningbo 315199, China; 3 Shanghai Peace Eye Hospital, Shanghai 200437, China

  • Received:2024-02-22 Online:2024-08-22 Published:2024-08-08
  • Contact: Wu Renyi, Email:wubasel@hotmail.com
  • Supported by:
    Natural Science Foundation of Xiamen, China (3502Z202374133); Huaxia Scientific Research Foundation (HXKY202301D004, HXKY202306A003)

摘要: miRNA是一类小的非编码RNA分子,参与青光眼发病的病理生理机制。miRNA具有作为青光眼早期检测和诊断生物标志物的潜力,研究miRNA有助于阐明青光眼发病的分子途径和发病机制,促进青光眼个性化医学的发展,并可应用于青光眼的治疗和非侵入性病情监测。但目前miRNA在青光眼研究应用中存在一些局限性,如缺乏样品收集、储存和DNA提取的标准化方案,样品的组织特异性及可及性较差,在不同人群中的可重复性较差等。通过解决这些局限性,不仅可以增强对miRNA在青光眼中作用的理解,也可以为个性化的治疗方法奠定基础。 (国际眼科纵览,2024, 48:248-254)


关键词: 青光眼, 微小RNA

Abstract: miRNAs are small non-coding RNA molecules that participate in the pathophysiological mechanisms of glaucoma. miRNA has the potential to serve as a biomarker for early detection and diagnosis of glaucoma. The study of miRNA in glaucoma helps to elucidate the molecular pathways and mechanisms of glaucoma, promote the development of personalized medicine for glaucoma, and can be applied to the treatment of glaucoma and non-invasive disease monitoring. Although miRNA research in glaucoma has good application prospects, there are also challenges and limitations, such as lack of standardized protocols for sample collection, storage, and DNA extraction, poor tissue specificity and accessibility of samples, and poor reproducibility in different populations. By addressing these limitations, not only can we enhance our understanding of the role of miRNA in glaucoma, but also pave the way for personalized medical methods. (Int Rev Ophthalmol, 2024, 48:  248-254)


Key words: glaucoma, miRNA